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In the first three years after treatment of patients with 
squamous cell carcinoma of upper aerodigestive tract 
(UADT), there is a high incidence of recurrences. After the 
third year, the occurrence of second primary tumor (SPT) is 
an important cause of morbimortality. Aim: To evaluate the 
incidence and the characteristics of the SPT in patients with 
squamous cell carcinoma of UADT, treated with curative 
intention. Methods: Retrospective study where the incidence, 
localization and treatment of SPT had been analyzed and 
survival rates were calculated. Results: Of the 624 analyzed 
cases, 59 (9.4%) had SPT during follow-up (4 synchronous 
and 55 metachronous). The SPT free survival rate ranged 
from 2 to 191.3 months (median of 42.5 months). In 20 
cases (33.9%) the SPT was diagnosed after the fifth year 
of follow-up. The most frequent site of STP was the UADT 
mucosa (49.1%), followed by the lungs (22.0%) and the 
esophagus (11.9%). The best survival after-SPT occurred in 
cases of UADT STP (32.2% in 5 years, median 16.2 months). 
Conclusion: The STP incidence was 9.4%. In 33.9% of the 
cases, the SPT was diagnosed after the fifth year of follow-up. 
The most frequent localization of STP was the UADT mucosa.
Keywords: head and neck neoplasms, neoplasms, second 
primary tumor.
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INTRODUCTION
Head and neck squamous cell carcinomas compri-
se about 3% of all malignancies; they may be located in 
several anatomical sites of the upper aerodigestive tract.1 
Treating these patients depends on several factors, such 
as experience, the tumor site and clinical stage, the patient 
medical status, and acceptance of therapy by patients.2-4
A high local and regional recurrence rate is seen 
within three years of treatment,5-10 which is the main cause 
of treatment failure in patients with upper aerodigestive 
tract squamous cell carcinoma.11,12 The onset of a second 
primary tumor after three years is a significant cause or 
morbidity and mortality.13,14
Billroth as having first documented the occurrence 
of several simultaneous neoplasms in the same patient in 
1860. Warren and Gates15 published in 1932 a major review 
of several case series of multiple primary neoplasms, and 
also reported 1,078 autopsies among which they found 40 
cases (3.7%) of multiple tumors. In this study, the authors 
proposed and used the following criteria for identifying 
multiple primary malignancies: confirming the diagnosis 
of malignancy, distinguishing among each tumor, and 
excluding the possibility of the tumor being metastatic.
Slaughter et al.16 in 1953 proposed the “condemned 
mucosa” theory to explain the high incidence of a second 
primary tumor in carcinomas induced by environmental 
factors. These authors introduced the “field cancerization” 
concept to explain the occurrence of multicentre squamous 
cell carcinomas in the mouth.
Day and Blot17 gathered data from nine population 
registries on cancer in the United States of America and 
assessed the risk of a second primary tumor in 21,371 
patients diagnosed with oral and pharyngeal cancer. They 
found a 3.7% yearly rate for the onset of a second primary 
tumor. Oral, pharyngeal and esophageal second primary 
tumors were 37% of these tumors; nose, larynx and lung 
tumors were 31% of these tumors; the remaining 34%, in 
decreasing order, were found in the lower digestive tract, 
the prostate, the urinary tract, the breast, and the female 
genital tract. The risk of developing a second primary 
tumor in the upper aerodigestive tract ranged from 4.2 to 
30 [esophagus (RR 23.0; CI 95% 19.0 - 26.0), mouth and 
pharynx (RR 20.0; CI 95% 18.0 - 22.0), larynx (RR 6.8; CI 
95% 5.5 - 8.4), nose and paranasal sinuses (RR 4.9; CI 
95% 2.0 - 10.1), and lungs (RR 4.2; CI 95% 3.9 - 4.6)]. The 
risk remained high for over 5 years after the diagnosis of 
the primary tumor, and was higher in patients aged 60 
years or less.
The purpose of this study was to assess the inciden-
ce and characterize the profile of second primary tumors 
in patients with head and neck squamous cell carcinomas, 
treated curatively at a single tertiary institution in a deve-
loping country.
MATERIAL AND METHOD
This retrospective study consisted of a review of 
the medical files of all previously untreated patients with 
upper aerodigestive tract squamous cell carcinoma who 
started treatment in 1988, 1994, and 1999. These years 
were chosen because full data were available in the Cancer 
Hospital Registry, which is a reviewed and computerized 
database.18
The upper aerodigestive tract areas included in this 
study were:
• mouth (lips and oral cavity);
• pharynx (naso, oro, and hypopharynx);
• nose and paranasal sinuses;
• larynx.
Clinical staging of second primary tumors was re-
viewed based on the reported data in the files, according 
to the 2002 version of the American Joint Committee on 
Cancer (AJCC).19 Warren and Gates’s criteria were applied 
in the diagnosis of second primary tumors.15
The date when the second primary tumor was 
confirmed by pathology was considered as the diagnostic 
date in our analysis; if this date was not available, the date 
when laboratory exam results were given was used. It this 
date was also not available, the consultation date - the 
medical diagnosis - was applied. Tumors diagnosed wi-
thin the first six months of the diagnosis of the first tumor 
were classified as synchronic; after six months, they were 
classified as metachronic.
The SSPS 10.0 for Windows software was used for 
the statistical analysis.20 Descriptive statistics for absolute 
and relative frequencies were applied to describe the cate-
gorical variables. Central tendency measures (mean and/or 
median) were applied to describe quantitative variables.
The Kaplan-Meier21 method was applied to calculate 
the probability of survival; curves were compared using the 
log-rank test. The second primary tumor-free survival rate 
was given by the time in months between the beginning 
of treatment and the diagnostic date of the second prima-
ry tumor. The survival rate after a second primary tumor 
was given by the time in months between the diagnostic 
date of the second primary tumor and the data in which 
the last objective information was gathered. Significance 
in the statistical tests was p ≤0.05.
RESULTS
There were 624 patients in our sample, admitted in 
1988, 1994 and 1999. The majority was male (520; 83.3%). 
The age ranged from 10 to 93 years (median - 58.6 years). 
The most frequent primary tumor sites were the mouth 
(251 cases; 40.2%), the oropharynx (150 cases; 24.1%), 
and the larynx (135 cases; 21.6%) (Table 1). There were 
293 clinical stage IV cases (46.9%) (Table 2).
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The follow-up period ranged from less than a 
month to 204.1 months (mean 49.8 months and median 
28.8 months). Second primary tumors were diagnosed and 
Among 59 second primary tumor cases, 12 (20.3%) 
were classified as clinical stage I, 9 (15.3%) were clinical 
stage II, 9 (15.3%) were clinical stage III, 17 (28.8%) were 
clinical stage IV with no distance metastases, and 8 (13.5%) 
had distance metastases at the time of diagnosis. Clinical 
staging could not be done in 4 cases (6.8%) (Table 4).
Radical treatment was possible in 33 cases (55.9%); 
surgery was the main approach. Palliative therapy was 
done in 16 cases (27.1%), in these cases, radiotherapy 
alone was the main approach (Table 5).
The 5-year survival after a second primary tumor 
was significantly higher (43.5% median 21.0 months) in 
patients undergoing radical treatment compared to the 
survival in patients treated with palliative therapy (median 
Table 1. Distribution of cases according to the tumor site.
Site number of cases (%)
Mouth 251 (40.2)
Oropharynx 150 (24.1)
Larinx 135 (21.6)
Hypopharynx 55 (8.8)
Paranasal sinus 18 (2.9)
Nasopharynx 15 (2.4)
TOTAL 624 (100.0)
Table 2. Clinical staging of 624 primary tumors.
Clinical stage number of cases (%)
0 3 (0.5)
I 93 (14.9)
II 97 (15.5)
III 137 (22.0)
IV 293 (46.9)
Ignored 1 (0.2)
recorded in 59 cases (9.4%) during follow-up. Tumors were 
synchronic in 4 cases (6.8%), and metachronic in 55 cases 
(93.2%). Three second primary tumor cases were lost to 
follow-up (5.1%).
The second primary tumor disease-free survival 
ranged from 2 to 191.3 months (mean 50.8 months and 
median 42.5 months). A diagnosis of a second primary 
tumor was made within the first follow-up year in 8 cases 
(13.5%). On the other hand, 20 cases (33.9%) were diag-
nosed after the fifth year of follow-up (Fig. 1).
The most frequent site of second primary tumors 
was the mucosa of the upper aerodigestive tract (29 ca-
ses, 49.1%), followed by the lung (13 cases, 22.0%), and 
the esophagus (7 cases, 11.9%). There were 6 cases that 
presented other tumors in the following sites: colon (1 
case), endometrium (1 case), thyroid (1 case), prostate (1 
case), kidney (1 case), and one leukemia case (Table 3).
The most frequent sites of second primary tumors 
in the upper aerodigestive tract were the oropharynx (14 
cases, 48.3%) and the mouth (9 cases, 31.0%). One case 
was considered as an occult second primary tumor rather 
than a regional recurrence, since the first tumor was a 
glottic in situ carcinoma that had been treated surgically. 
This diagnosis was made 30.4 months after treatment of 
the primary tumor (Table 3).
Figure 1. Cummulative frequency of the diagnoses of second primary 
tumors relative to the follow-up period in 624 cases.
Table 3. Distribution of second primary tumor cases according to the 
site.
Site of 2ndTa número de casos (%)
Upper aerodigestive tractb 29 (49,1)
Oropharynx 14 (48,3)
Mouth 9 (31,0)
Larynx 3 (10,3)
Hypopharynx 2 (6,9)
Occult primary 1 (3,5)
Lungs 13 (22,0)
Esophagus  7 (11,9)
Stomach 4 (6,8)
Others  6 (10,2)
TOTAL 59 (100,0)
Key: a2ndT: second primary tumor; bupper aerodigestive tract
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-  8.1 months) or supportive care (median 5 months). The 
longest survival period in the group that received pallia-
tive care was 31.1 months; survival was 11.2 months in 
the group that received only supportive care (p <0.001) 
(Fig. 2).
The 5-year survival in patients with a clinical stage 
I, II or III second primary tumor was also significantly 
higher (34.4%, median 13.7 months) compared with the 
clinical stage IV group without metastases (median 15.6 
months) and to the clinical stage IV with metastases group 
(median 6.3 months) (p=0.003) (Fig. 3). Three patients in 
the clinical stage IV without metastases group were alive 
with no evidence of active disease. All patients with upper 
aerodigestive tract second primary tumors (mouth, clinical 
stage T4N0M0; oropharynx, T4N0M0; and occult primary 
TxN2aM0) were followed-up for 34.2 to 46.0 months; a 
fourth patient with an upper aerodigestive tract second 
primary tumor (base of tongue T2N2bM0) was lost to 
follow-up after 80.2 months. The highest survival was 
12.3 months in the clinical stage IV group with metastases.
Survival varied depending on the site of the se-
cond primary tumor (Fig. 4) (p=0.005). Only the patients 
with upper aerodigestive tract and stomach tumors were 
followed up for longer than 5 years. The 5-year survival 
was 32.2% (median 16.2 months) in patients with upper 
aerodigestive tract second primary tumors. Two patients 
with second primary tumors of the stomach were alive; 
one was followed-up for 8.4 months and received sup-
portive care from the diagnosis of the second primary 
tumor, while the other was followed-up for 54.8 months, 
underwent radical surgery, and had no evidence of active 
disease. A third patient, also treated with radical surgery, 
had no evidence of disease after 87.6 months, but after 
that was lost to follow-up.
There were 13 cases with second primary tumor of 
the lungs; of these, only one patient remained alive, with 
no evidence of active disease, at 49.3 months follow-up. 
Table 4. Distribution of second primary tumor cases according to 
the clinical stage.
Clinical stage number of cases (%)
I 12 (20.3)
II 9 (15.3)
III 9 (15.3)
IV local-regional 17 (28.8)
IV metastasis 8 (13.5)
No information 4 (6.8)
TOTAL 59 (100.0)
Table 5. Distribution of second primary tumor cases according to the 
treatment.
Variable Category number of cases (%)
Treatment
Radical 33 (55,9)
Palliative 16 (27,1)
Supportive care 10 (17,0)
Radical treatment
Surgery 23 (69,7)
Surgery and RTa  4 (12,1)
RT  4 (12,1)
RT and CTb 2 (6,1)
Palliative treatment
RT  6 (37,5)
RT e CT  5 (31,2)
CT  3 (18,8)
Surgery  2 (12,5)
 Legenda: aRT: Radiotherapy; 
bCT: Chemotherapy
Figure 2. Survival curves after second primary curves according to the 
type of treatment of the second tumor.
Figure 3. Survival curves after second primary curves according to the 
clinical stage of the second tumor.
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This tumor had been classified as T1N0M0 clinical stage 
I, and was treated with surgery. The median survival in 
patients with second primary tumors of the lung was 7.3 
months.
The longest survival in the group of patients with 
second primary tumors of the esophagus was 15.6 months 
(median 9.7 months). Among other tumors, which compri-
sed a heterogeneous group of malignancies, one patient 
with a thyroid papilliferous carcinoma was alive at 51.7 
months and one patient with a prostate adenocarcinoma 
was alive at 53.3 months follow-up.
DISCUSSION
In this study we reviewed the files of all patients 
with squamous cell carcinoma of the upper aerodigestive 
tract that were treated at our institution in 1988, 1994 
and 1999. These years were not chosen randomly. More 
recently, the hospital has organized a computerized data-
base containing detailed social, demographic, and clinical 
data on patients (Cancer Hospital Registry). We initially 
we registered patients admitted in 1988, 1994,18 and more 
recently 1999, after a detailed review of the files. We thus 
chose these three years to make it easier to find the cases 
of interest for this study and to gather social, demographic, 
and clinical data.
Of 624 cases in this study, 59 (9.4%) developed 
second primary tumors. The incidence of second primary 
tumors in patients treated for upper aerodigestive tract 
tumors appears to increase in a relatively constant form 
with time. Vikram et al.13 reported a 6% yearly increase 
rate, where the incidence was 14.03% in his series. Day 
and Blot17 estimated that the rate of development of a 
second primary tumor was 3.7% a year. Our follow-up 
ranged from less than a month to 17 years (median 2.4 
years). If we take into account our median follow-up time, 
the incidence of second primary tumors was 9.4%, and is 
placed between the two authors mentioned above.
Second primary tumors were diagnosed in 33.9% 
of cases after 5 years of follow-up. Di Martino et al.22 also 
found that a diagnosis of second primary tumors was 
made in 42% of patients after 5 years of follow-up. Fran-
co et al.23 published a case control study and concluded 
that follow-up time is a significant factor in relation to the 
development of a second primary tumor.
Sturgis and Miller14 published a review and conclu-
ded that the risk of developing a second primary tumor 
is constant with time, and that these tumors are the main 
cause of failed treatments of upper aerodigestive tract 
initial stage squamous cell carcinomas. Franchin et al.24 
studied only patients with initial laryngeal tumors treated 
with radiotherapy alone, and also found that the onset of 
a second primary tumor was the main cause of death in 
this group.
The main second primary tumor sites were the 
mucosa of the upper aerodigestive tract (49.1%), the lun-
gs (22.0%), and the esophagus (11.9%), all of which are 
tumors with the same environmental risk factors. Leon et 
al.25 and Day and Blot17 also showed that the incidence of 
second primary tumors was higher in the upper aerodiges-
tive tract. On the other hand, most of the second primary 
tumors in Vikram et al.’s13 series were in the esophagus 
(44%) and lungs (37.5%).
In our study, second primary tumors were classified 
according to the clinical stage; their biological behavior 
varies, however, which may compromise some compari-
sons. Patients with clinical stage IV upper aerodigestive 
tract tumors are often candidates for radical treatment, 
which offers significant cure rates, since patients with 
clinical stage IV lung tumors are metastatic.
The indication for radical treatment was significantly 
related with the clinical stage (I, II or III) of patients with 
second primary tumors (p<0.001); the time of diagnosis 
of a second primary tumor was unrelated with the clinical 
stage or survival.
The 5-year survival rate after a second primary 
tumor clinical stages I, II, and III, and those undergoing 
radical treatment, was significantly higher (p=0.003 and 
p<0.001).
The site of the second primary tumor also affected 
survival (p=0.005); the best rates occurred in patients with 
second primary tumor of the upper aerodigestive tract 
(32.2% in 5 years). It should be noted that tumors in the 
mucosa of the upper aerodigestive tract can be assessed lo-
cally and regionally in follow-up visits of patients with head 
and neck cancers, which may favor an early diagnosis.
On the other hand, the median survival time among 
the seven cases with a second primary tumor of the eso-
phagus in our study was 9.7 months (maximum survival 
was 15.6 months). Survival was short (median 7.3 months) 
Figure 4. Survival curves after second primary curves according to 
the second tumor site.
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among the 13 cases of second primary tumors of the lung; 
only one patient, classified as clinical stage I, was alive 
after 49.3 months follow-up.
Several studies have assessed the routine use of 
triple endoscopy (upper digestive endoscopy, bronchos-
copy, and nasofibrolaryngoscopy) in the initial evaluation 
of patients with head and neck tumors, with the aim of 
diagnosing a second primary tumor.26-31 It is important to 
assess the impact of a diagnosis of second primary tumors 
on the survival of this group of patients by comparing them 
with asymptomatic patients undergoing routine follow-up 
not including endoscopy.
CONCLUSION
Of 624 cases in this study, 59 (9.4%) developed 
second primary tumors. These tumors were synchronic 
in 4 cases (6.8%), and metachronic in 55 cases (93.2%).
The diagnosis of a second primary tumor was made 
after a 5-year follow-up period in 33.9% of cases.
The upper aerodigestive tract was most frequently 
affected by second primary tumors (49.2%), followed by 
the lungs (22.0%), and the esophagus (11.9%).
The longest survival period after second primary 
tumors was seen in the group of patients with second 
primary tumors in the upper aerodigestive tract (32.2% 
5-year survival rate, median 16.2 months).
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